Business Standard

We're geared to launch a new molecule every 1-2 years: Biocon Biologics MD

In an interview, Arun Chandavarkar explains why a company must continue investing in R&D despite the impact on short-term Ebitda

Arun Chandravarkar, MD, Biocon Biologics
Premium

Arun Chandravarkar, MD, Biocon Biologics

Sohini Das Mumbai
The market share that Biocon Biologics' insulin Glargine injection has gained in the US has been partially offset by price erosion in the company's key products. In an interview, Arun Chandavarkar, MD, Biocon Biologics explains to Sohini Das why a company must continue investing in R&D even if that affects short-term Ebitda. Edited excerpts:

You have gained market share in the US for your insulin Glargine injections. What is

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jul 29 2022 | 3:24 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com